[Therapeutic efficacy of quercetin in patients with is ischemic heart disease with underlying metabolic syndrome].
Purpose - to evaluate the efficacy of using quersetin in patients with IHD against a background of metabolic syndrome. The authors have examined 55 patients with a chronic form of ischemic heart disease (IHD) with metabolic syndrome (MS), 35 patients out of them (the basic group) against a background of the standard therapy of IHD (β-adrenoblocker, a nitropreparation, an inhibitor of the angiotensis - converting enzyme, acetylsalicylic acid, statins) received the quercetin agent by means of an infusion. They also analyzed general clinical findings, the parameters of the stale of lipid peroxidation (LPO), the antioxidants defence (AOD) and the oxidative protein modification (OPM) as well as the results of diurnal ECG monitoring. As a result of a course of treatment carried out in the patients of the basic group, the number and duration of ischemic episodes reliably decreased, the number of patients with supraventricular extrasystoles diminished (SE) up to 5% (p<0,05), whereas with isolated ventricular extrasystoles (VE-up to 13% (p<0,05)), with ventricular disturbances of the rhythin of high gradations according to B. Laun (VDRHG) - up to 5% (p<0,05), a significant increase of the lever of reduced hemoglobin (RH) by 13,41% (p<0,05) and a decrease of the content of malonic aldehyde (MA) by 14,9% (p<0,05) have been noted. Qnercetin possesses an antiischemic, antiarrhythmic effect, exerts a regulating influence on vegetative homeostassin, oxidant disturbances, determining its efficacy, while using it in patients with IHD with underlying MS.